Ankündigung • 3h
Merit Medical Systems, Inc. Announces Executive Changes Merit Medical Systems, Inc. announced that Sheri Lewis had agreed to join Merit as Executive Vice President of Global Operations, effective August 31, 2026. Ms. Lewis brought three decades of experience across global operations, manufacturing, and supply chain management. She previously held senior roles at SkinHealth Systems, Inc., Avantor, Medtronic, and Honeywell, leading global manufacturing, distribution, logistics, supply chain, quality, regulatory, environmental health and safety, and operational excellence functions across large, complex organizations. To support continuity, Mr. Peterson would move into the role of Senior Advisor, where he would help ensure a smooth transition through March 5, 2027. Mr. Peterson had held leadership roles across Merit’s operations and engineering functions, most recently serving as Chief Operating Officer for the past four years. Throughout his career, he had strengthened product quality, improved on-time delivery, advanced operational efficiencies, and driven cost reductions. He also helped navigate supply chain constraints, raw material shortages, and the operational challenges of the COVID-19 pandemic. Mr. Peterson had consistently shown a deep commitment to supporting employees and their well-being. Live-News • 18h
Merit Medical Taps Sheri Lewis for Global Operations EVP as COO Plans Transition Merit Medical Systems has appointed Sheri Lewis as Executive Vice President of Global Operations, effective 31 August 2026, while current COO Mr. Peterson will transition to Senior Advisor until 5 March 2027 before ending his 32-year tenure with the company.
The company highlights Lewis’s three decades of experience in global operations, manufacturing and supply chain roles at SkinHealth Systems, Avantor, Medtronic and Honeywell, and is aiming for continuity through an overlapping transition period with the outgoing COO.
Merit Medical Systems shares trade at US$89.26, with the stock up 20.6% over the past 30 days.
This kind of planned succession in a core operational role can matter for execution risk. The defined overlap between Lewis and Peterson may reduce disruption in manufacturing and supply chain decisions, which is especially relevant if the company is managing complex global production and product delivery. Recent Insider Transactions • Aug 06
Chief Operating Officer recently sold US$1.8m worth of stock On the 4th of August, Neil Peterson sold around 21k shares on-market at roughly US$85.00 per share. This transaction amounted to 68% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Neil's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • Aug 05
Chief Operating Officer notifies of intention to sell stock Neil Peterson intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of August. If the sale is conducted around the recent share price of US$85.00, it would amount to US$1.8m. Neil currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$6.7m more than they bought, via options and on-market transactions in the last 12 months. Live-News • Aug 02
Merit Medical Systems Raises 2026 Sales and Earnings Targets After Strong Q2 Performance Merit Medical Systems raised its full-year 2026 adjusted EPS guidance and sales forecast after reporting second quarter earnings that were ahead of expectations, citing strong revenue growth, better U.S. sales and improved operating margin and earnings per share.
This guidance increase signals management’s higher confidence in the business trajectory and gives analysts more concrete financial targets, which has already led to higher external forecasts for Merit Medical Systems.
The stock last traded at $85.01, with the share price up 37.1% over the past 90 days, reflecting a strong recent run into and around the latest results.
The key read-through is that Merit Medical Systems is tying its longer-term guidance to current operating trends, which can sharpen focus on execution risk if margins or U.S. demand soften against these higher targets. Reported Earnings • Jul 31
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: EPS: US$0.65 (up from US$0.55 in 2Q 2025). Revenue: US$418.8m (up 9.5% from 2Q 2025). Net income: US$38.8m (up 19% from 2Q 2025). Profit margin: 9.3% (up from 8.5% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) also surpassed analyst estimates by 6.8%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Ankündigung • Jul 31
Merit Medical Systems, Inc. Raises Earnings Guidance for the Fiscal Year Ending December 31, 2026 Merit Medical Systems, Inc. raised earnings guidance for the fiscal year ending December 31, 2026. The company have increased 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first half of 2026 and remain confident in team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year. For the year, the company expects total revenue of $1.631 billion to $1.643 billion compared to previous guidance of $1.612 billion to $1.634 billion. Ankündigung • Jul 03
Merit Medical Systems, Inc. to Report Q2, 2026 Results on Jul 30, 2026 Merit Medical Systems, Inc. announced that they will report Q2, 2026 results After-Market on Jul 30, 2026 Live-News • Jun 08
Merit Medical Expands Oncology Portfolio While Facing Margin Pressures in Key Regions Merit Medical Systems is being highlighted for its broad product portfolio and continued spending on research and development.
The company has expanded its oncology offering through the acquisition of View Point Medical, adding capabilities in breast cancer localization procedures.
Management is also dealing with headwinds from tariffs, weaker performance in the OEM segment, and pricing pressure in China.
The focus on oncology and R&D indicates that management is emphasizing higher-value clinical areas, while the View Point Medical deal adds another procedure type to the toolkit.
At the same time, tariffs, OEM softness, and China pricing pressure mean investors may want to pay close attention to margins and regional trends when assessing the risk/return trade-off for this stock. Recent Insider Transactions Derivative • May 22
Independent Director exercised options to buy US$1.4m worth of stock. On the 20th of May, Thomas Gunderson exercised options to buy 21k shares at a strike price of around US$52.17, costing a total of US$1.1m. This transaction amounted to 54% of their direct individual holding at the time of the trade. Thomas currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months. Ankündigung • May 21
Merit Medical Systems, Inc. Appoints Scott R. Ward to Board of Directors and Board Committees Merit Medical Systems, Inc. announced that shareholders elected Scott R. Ward to the company’s Board of Directors at Merit’s annual meeting of shareholders. Mr. Ward was elected to serve a three-year term. Mr. Ward brings more than 40 years of experience in the healthcare and medical device industry, including nearly three decades at Medtronic, where he held senior leadership roles such as senior vice president and president of the cardiovascular, neurological, and diabetes businesses. He most recently served as CEO, President and Chairman of Cardiovascular Systems, Inc., leading the company through a period of expansion and its acquisition by Abbott. Mr. Ward is also the founder of Raymond Holdings, a firm focused on venture capital, strategy, and advisory services for medical technology and life sciences companies, and has served on numerous public and private company boards. Merit’s Board of Directors has appointed Mr. Ward to serve on its Governance and Sustainability and Finance and Operating Committees. Major Estimate Revision • May 07
Consensus EPS estimates increase by 13% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from US$2.48 to US$2.81. Revenue forecast steady at US$1.62b. Net income forecast to grow 24% next year vs 13% growth forecast for Medical Equipment industry in the US. Consensus price target down from US$98.36 to US$90.64. Share price fell 8.6% to US$62.33 over the past week. Price Target Changed • May 04
Price target decreased by 7.9% to US$90.64 Down from US$98.36, the current price target is an average from 11 analysts. New target price is 46% above last closing price of US$62.01. Stock is down 34% over the past year. The company is forecast to post earnings per share of US$2.81 for next year compared to US$2.17 last year. Ankündigung • May 03
Merit Medical Systems, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2026 Merit Medical Systems, Inc. updated earnings guidance for the full year ending December 31, 2026. for the year, the company expects Total Revenue in the range of $1.612 billion - $1.634 billion against $1.610 billion - $1.630 billion expected previously. Reported Earnings • May 01
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$0.69 (up from US$0.51 in 1Q 2025). Revenue: US$381.9m (up 7.5% from 1Q 2025). Net income: US$41.0m (up 36% from 1Q 2025). Profit margin: 11% (up from 8.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 40%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Ankündigung • Apr 02
Merit Medical Systems, Inc., Annual General Meeting, May 13, 2026 Merit Medical Systems, Inc., Annual General Meeting, May 13, 2026. Ankündigung • Mar 17
Merit Medical Systems, Inc. Launches Resilience Through-The-Scope Esophageal Stent Merit Medical Systems, Inc. announced the US commercial release of the Resilience Through-the-Scope (TTS) Esophageal Stent. The Resilience stent is the newest product in Merit’s Endoscopy portfolio, joining a comprehensive offering of treatment options for patients with disease in the esophagus. The new stent is indicated for treatment of esophageal fistulas and strictures (narrowing) caused by malignant tumors. Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Symptoms of esophageal cancer include trouble swallowing, regurgitation, and chest pain. These gradually worsen over time, with an increase in pain when swallowing as the esophagus narrows from the growing cancer. To care for this patient population, the Resilience stent was developed with proprietary anti-migration flanges to anchor the stent in place. In addition, it is designed to demonstrate the greatest migration resistance among currently available TTS stents. A single-handed deployment system provides clinicians with control for easy and accurate placement. To meet a variety of clinical needs, Resilience is the only stent on the market offered in sizes 14 mm x 50 mm, 17 mm x 50 mm, and 20 mm x 50 mm. Reported Earnings • Feb 25
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: US$2.17 (up from US$2.07 in FY 2024). Revenue: US$1.52b (up 12% from FY 2024). Net income: US$128.5m (up 6.8% from FY 2024). Profit margin: 8.5% (down from 8.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 25
Merit Medical Systems, Inc. Provides Earnings Guidance for the Year Ending December 31, 2026 Merit Medical Systems, Inc. provided earnings guidance for the year ending December 31, 2026. For the year, the company expects total revenue of $1.610 billion to $1.630 billion, up 6% - 8% year-over-year on a reported basis and up 5% - 7% year-over-year on a constant currency basis. Ankündigung • Jan 10
Merit Medical Systems, Inc. Announces Earnings Guidance for Fourth Quarter Ended December 31, 2025 Merit Medical Systems, Inc. announced earnings guidance for the fourth quarter ended December 31, 2025. For the period, the company expects revenue in the range of approximately $389 million to $395 million, up approximately 10% to 11% year-over-year. Recent Insider Transactions Derivative • Jan 07
Chief Operating Officer notifies of intention to sell stock Neil Peterson intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of January. If the sale is conducted around the recent share price of US$90.00, it would amount to US$450k. Since March 2025, Neil has owned 16.61k shares directly. Company insiders have collectively sold US$24m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Nov 23
Founder & Chairman recently sold US$1.7m worth of stock On the 20th of November, Fred Lampropoulos sold around 20k shares on-market at roughly US$85.13 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Fred has been a net seller over the last 12 months, reducing personal holdings by US$9.6m. Ankündigung • Nov 14
Merit Medical Systems, Inc. Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY Cell-Impermeable Endoprosthesis Merit Medical Systems, Inc. announced that the U.S. Centers for Medicare & Medicaid Services ("CMS") has notified Merit that its application for Transitional Pass-Through ("TPT") incremental payment for WRAPSODY Cell-Impermeable Endoprosthesis ("CIE") procedures in the outpatient and ambulatory surgery center ("ASC") settings requires further consideration prior to CMS making a final decision. CMS notified Merit that it has deferred Merit's application for the WRAPSODY CIE to the Calendar Year 2027 Outpatient Prospective Payment System rule, making January 1, 2027, the earliest possible effective date. Ankündigung • Nov 06
Merit Medical Systems, Inc. Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (Avf) Arm of the Wrapsody Arteriovenous Access Efficacy (Wave) Trial Merit Medical Systems, Inc. announced positive findings from the randomized AVF arm of the WAVE trial. These findings were presented during the Late-Breaking Clinical Trials session on November 4, 2025, at the Vascular Interventional Advances (VIVA)3 conference held in Las Vegas, Nevada. The WAVE trial was designed to capture the performance of the WRAPSODY CIE. TLPP and ACPP outcomes were used to evaluate the ability of the device to restore functional vascular access in trial patients. Forty-three centers across the United States, South America, and the United Kingdom participated in the trial. In the randomized arm of the WAVE trial, 245 hemodialysis patients with evidence of venous obstructions in their AVF were treated with either the WRAPSODY CIE (n=122) or PTA (n=123). Twenty-four months following treatment, TLPP was significantly higher among patients treated with the WRAPSODY CIE versus PTA (48.6% vs. 29.8%. Reported Earnings • Nov 02
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: EPS: US$0.47 (down from US$0.49 in 3Q 2024). Revenue: US$384.2m (up 13% from 3Q 2024). Net income: US$27.8m (down 2.4% from 3Q 2024). Profit margin: 7.2% (down from 8.4% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) missed analyst estimates by 2.1%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Ankündigung • Oct 31
Merit Medical Systems, Inc. Updates Earnings Guidance for the Fiscal Full Year ending December 31, 2025 Merit Medical Systems, Inc. updated earnings guidance for the fiscal full year ending December 31, 2025. For the period, the company expects Net Sales to be in the range of $1.502 billion to $1.515 billion as compared to previous guidance of $1.495 billion to $1.507 billion. Ankündigung • Oct 03
Merit Medical Systems, Inc. to Report Q3, 2025 Results on Oct 30, 2025 Merit Medical Systems, Inc. announced that they will report Q3, 2025 results After-Market on Oct 30, 2025 Recent Insider Transactions Derivative • Sep 05
Founder & Chairman exercised options and sold US$4.4m worth of stock On the 29th of August, Fred Lampropoulos exercised 161.15k options at around US$55.73, then sold 126k of the shares acquired at an average of US$90.54 per share and kept the remainder. Since March 2025, Fred's direct individual holding has decreased from 1.15m shares to 1.11m. Company insiders have collectively sold US$21m more than they bought, via options and on-market transactions in the last 12 months. Ankündigung • Aug 19
Merit Medical Systems, Inc Announces Successful Enrollment of the First Patient in the Wrap North America Registry Merit Medical Systems, Inc. announced the successful enrollment of the first patient in the WRAP North America registry. The WRAP North America registry is designed to enroll up to 250 US and Canadian patients on hemodialysis who experience obstructions, such as stenosis (narrowing) or occlusion (blockage) in the veins required for dialysis (vascular access). The WRAPSODY CIE is designed to help clinicians restore vascular access in patients on he modialysis who experience such obstructions. The study protocol provides for evaluation of clinical outcomes in patients treated with the WRAPSODY CIE over three years. The superior performance of the WRAPSODY CIE in the clinical trial setting was previously demonstrated in the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The WAVE trial included two arms. In the randomized [1] arm, patients with an arteriovenous fistula (AVF) were treated with the WRAPSodies CIE or percutaneous transluminal angioplasty (PTA). In the non-randomized arm, clinical outcomes of patients with an arteriovenously graft (AVG) were compared to historical outcomes (i.e., performance goals) of AVG patients treated with previous-generation covered stents. The WRAPSODY CIE's ability to restore vascular access for patients on hemodialysis where experience obstructions. The WRAPSODY Cie's real-world effectiveness will help address critical questions regarding the broader impact of its use in clinical practice. The WRAPSODY CIA is intended to add to Merit's growing portfolio of clinical evidence supporting the WRAPSODY CIE. Real-world outcomes associated with the use of the WRAPSODY Cie are also being evaluated in the WRAP Global registry, also being conducted by Merit, which was designed to enroll up to 500 patients outside of North America. Final enrollment in the WRAP Global registry is expected by the end of 2025. On December 19, 2024, the WRAPSODY CIE received premarket approval from the US Food and Drug Administration (FDA). On April 30, 2025, the device was approved by Health Canada. The WRAPSODY C IE previously received the Conformite Europeenne (CE) Mark for commercial use in the European Union and is available in Brazil. Any forward-looking statements set forth in this release are subject to risks and uncertainties such as those described in Merit's filings with the U. S. Securities and Exchange Commission ("SEC"). Ankündigung • Aug 07
Merit Medical Systems, Inc. Launches Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology Merit Medical Systems, Inc. announced the US commercial release of the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Securement Technology. The Prelude Wave is the latest innovation in Merit's comprehensive Access portfolio, which includes a wide range of dilators, micro-access systems, sheath introducers, and guide sheath. A low-profile, hydrophilic sheath with best-in-class insertion and sheath retention, the Prelude Wave with SnapFix technology is designed with features which may aid in the reduction of arterial spasm and occlusion as physicians perform radial access procedures. Radial access offers many well-documented benefits compared to the femoral approach,1 but there remain opportunities to improve patient outcomes, as radial artery spasm (narrowing) and occlusion (blockage) can still occur. Radial artery spasm is reported in up to 20% of patients,2 and approximately 4.6% will have a radial artery inclusion, both of which can lead to patient discomfort and other complications.4,5 Sheath features, such as a hydrophilic coating, a low profile, and tapered transitions have been shown to help reduce the risks of radial arterial spasm and occ Lusion as well as improve patient comfort. In addition, securement devices utilized to stabilize hydrophilic sheath during procedures have been linked to reported issues in 30% of cases, leading to procedural inefficiency.7 A securement device specifically developed for sheath may help alleviate the challenges physicians face. To meet these clinical needs, Merit innovated the Prelude Wave, a next-generation sheath with a unique securement feature. Compared to the leading competitor, the Prelude Wave offers twice the lubricity, twice the resistance to buckling and kinking, and requires 40% less insertion force.8 A first of its kind, SnapFix technology provides twice the adhesive strength, with physicians rating its performance and ease of use superior to the leading competitor. Reported Earnings • Jul 31
Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat Second quarter 2025 results: EPS: US$0.55 (down from US$0.61 in 2Q 2024). Revenue: US$382.5m (up 13% from 2Q 2024). Net income: US$32.6m (down 8.8% from 2Q 2024). Profit margin: 8.5% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Ankündigung • Jul 31
Merit Medical Systems, Inc. Revises Earnings Guidance for Fiscal Year Ending December 31, 2025 Merit Medical Systems, Inc. revised earnings guidance for Fiscal Year Ending December 31, 2025. For the period, the company now expects net sales of $1.495 million - $1.507 billion compared to prior guidance of $1.480 - $1.501 billion. 2025 Net Sales Guidance - % Change from Prior Year (GAAP) updated to 10% to 11% from 9% to 11%. Buy Or Sell Opportunity • Jul 09
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 4.9% to US$96.01. The fair value is estimated to be US$79.93, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 6.8% per annum. Earnings are also forecast to grow by 14% per annum over the same time period. Ankündigung • Jul 04
Merit Medical Systems, Inc. to Report Q2, 2025 Results on Jul 30, 2025 Merit Medical Systems, Inc. announced that they will report Q2, 2025 results After-Market on Jul 30, 2025 Recent Insider Transactions Derivative • Jun 15
CFO & Treasurer notifies of intention to sell stock Raul Parra intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of June. If the sale is conducted around the recent share price of US$93.75, it would amount to US$1.4m. Since December 2024, Raul's direct individual holding has increased from 11.81k shares to 13.64k. Company insiders have collectively sold US$18m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Jun 11
Founder recently sold US$952k worth of stock On the 5th of June, Fred Lampropoulos sold around 10k shares on-market at roughly US$95.19 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$1.9m. Fred has been a net seller over the last 12 months, reducing personal holdings by US$7.4m. Recent Insider Transactions Derivative • Jun 01
Independent Director notifies of intention to sell stock David Floyd intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of May. If the sale is conducted around the recent share price of US$96.79, it would amount to US$486k. Since March 2025, David has owned 14.00k shares directly. Company insiders have collectively sold US$16m more than they bought, via options and on-market transactions in the last 12 months. Board Change • Jun 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Independent Director Silvia Perez was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • May 16
Lead Independent Director notifies of intention to sell stock F. Millner intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of May. If the sale is conducted around the recent share price of US$96.47, it would amount to US$2.1m. Since June 2024, Millner has owned 29.96k shares directly. Company insiders have collectively sold US$14m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • May 01
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$2.39 to US$2.13 per share. Revenue forecast steady at US$1.48b. Net income forecast to grow 5.9% next year vs 16% growth forecast for Medical Equipment industry in the US. Consensus price target down from US$118 to US$107. Share price was steady at US$94.45 over the past week. Reported Earnings • Apr 25
First quarter 2025 earnings: EPS exceeds analyst expectations First quarter 2025 results: EPS: US$0.51 (up from US$0.49 in 1Q 2024). Revenue: US$355.4m (up 9.8% from 1Q 2024). Net income: US$30.1m (up 6.8% from 1Q 2024). Profit margin: 8.5% (down from 8.7% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 14%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Ankündigung • Apr 09
Merit Medical Launches the Ventrax™ Delivery System Merit Medical Systems, Inc. announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit's latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of solutions to improve cardiac interventions, including the HeartSpan®?, Worley™?, Prelude SNAP™?, and SafeGuard Focus®? product lines. Ventrax is intended to facilitate placement of devices used in ablation procedures commonly performed to treat an abnormally fast heartbeat known as ventricular tachycardia (VT). Ventricular arrhythmias, which include VT, are believed to cause approximately three out of four sudden cardiac deaths, which result in an estimated 184,000-450,000 lives lost in the United States each year. The all-in-one device provides a streamlined pathway for ablation catheters to enter the left ventricle through the aorta, an approach known as retrograde aortic access. Key features of the Ventrax Delivery System include a 95-cm sheath designed to access desired target locations. An ultralow-profile transition between its sheath and pigtail-dilator offers smooth insertion, and an angled tip enhances the reach of an ablation catheter. VT ablation is one of the fastest growing areas in electrophysiology. Many physicians are using retrograde aortic access for VT procedures, and researchers are increasingly investigating the technique. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$88.48, the stock trades at a forward P/E ratio of 37x. Average trailing P/E is 26x in the Medical Equipment industry in the US. Total returns to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$80.69 per share. Ankündigung • Apr 08
Merit Medical Systems, Inc. to Report Q1, 2025 Results on Apr 24, 2025 Merit Medical Systems, Inc. announced that they will report Q1, 2025 results After-Market on Apr 24, 2025 Ankündigung • Apr 03
Merit Medical Systems, Inc., Annual General Meeting, May 14, 2025 Merit Medical Systems, Inc., Annual General Meeting, May 14, 2025. Ankündigung • Mar 27
Merit Medical Systems, Inc. Updates ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD Merit Medical Systems, Inc. announced that the American Society for Gastrointestinal Endoscopy (ASGE) updated its guideline on the diagnosis and management of gastroesophageal reflux disease (GERD) to include Transoral Incisionless Fundoplication (TIF 2.0) and TIF 2.0 Consecutive Transoral Incisionless Fundoplication (cTIF) procedures as evidence-based approaches to care. GERD occurs when stomach acid flows into the esophagus, causing irritation of the tissue lining. Uncomfortable symptoms can include heartburn, upper stomach or chest pain, trouble swallowing, and chronic cough. A common chronic condition, GERD affects about 20% of people in the United States.1 Left untreated, GERD can lead to other serious complications over time. A minimally invasive therapy, the TIF 2.0 procedure reconstructs the gastroesophageal valve and restores its function as a reflux barrier. TIF 2.0 can also be combined consecutively with a surgical hiatal hernia repair, in a procedure referred to as cTIF. To diagnose and manage GERD, the ASGE developed an evidence-based guideline using the Grading of Recommendations Assessment, Development, and Evaluation framework. Updated from the 2014 ASGE guideline, the revised guideline addresses the role endoscopic anti-reflux therapy plays in the management and treatment of GERD, including TIF 2.0 and cTIF procedures. To help treat this patient population, Merit Medical offers the EsophyX® Z+ Device for use during TIF 2.0 and cTIF procedures. Designed to restore anatomy and reconstruct the gastroesophageal valve, the EsophyX Z+ Device helps provide relief of GERD symptoms and reduce acid reflux that can lead to long-term complications and risk. The EsophyX Z+ Device with SerosaFuse Fasteners and Accessories is indicated for use in transoral tissue approximation, full thickness plication and ligation in the GI tract and is indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy. It is also indicated to narrow the junction and reduce hiatal hernia =2cm in size in patients with symptomatic chronic gastroesophageal reflux disease. Patients with hiatal hernias larger than 2cm may be included, when a laparoscopic hiatal hernia repair reduces the hernia to 2cm or less. Ankündigung • Mar 11
Merit Medical Systems, Inc. Announces Enrollment of the First Patient in Its Multicenter, Prospective Study of the Bloom Micro Occluder System for the Treatment of Patent Ductus Arluder System Merit Medical Systems, Inc. announced enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in premature infants (PREEMIE study). PDA is a congenital heart condition that occurs when the ductus arteriosus, a blood vessel connecting the aorta and pulmonary artery, does not close following birth. The condition is common in premature, low-birth-weight infants. A PDA affects the way blood flows through a baby's lungs. A hemodynamically significant or large PDA (hsPDA) can negatively affect a baby's health and require treatment to close the opening. Today, minimally invasive treatment options offer alternatives to surgery or delayed treatment after watchful waiting. Merit proposes to enroll at least 55 premature infants with hsPDA at up to ten U.S. study sites. To be eligible, patients must weigh between 600 g and 2,500 g, which are considered "extremely low birth weight" and "low birth weight," respectively. Merit intends to evaluate safety and efficacy through six months as part of the premarket approval application. The PREEMIE study is an Investigational Device Exemption (IDE) study. The Bloom Micro Occluder System is not currently approved to treat PDA. Recent Insider Transactions • Mar 10
Founder recently sold US$3.6m worth of stock On the 5th of March, Fred Lampropoulos sold around 34k shares on-market at roughly US$104 per share. This transaction amounted to 2.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Fred's only on-market trade for the last 12 months. Recent Insider Transactions • Mar 05
CFO & Treasurer recently sold US$1.2m worth of stock On the 28th of February, Raul Parra sold around 12k shares on-market at roughly US$98.81 per share. This transaction amounted to 51% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Raul has been a net seller over the last 12 months, reducing personal holdings by US$1.7m. Recent Insider Transactions Derivative • Mar 02
Chief Human Resources Officer notifies of intention to sell stock Michel Voigt intends to sell 18k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of February. If the sale is conducted around the recent share price of US$102, it would amount to US$1.8m. Company insiders have collectively sold US$4.9m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 26
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: US$2.07 (up from US$1.64 in FY 2023). Revenue: US$1.36b (up 7.9% from FY 2023). Net income: US$120.4m (up 28% from FY 2023). Profit margin: 8.9% (up from 7.5% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 26
Merit Medical Systems, Inc. Provides Earnings Guidance for the Fiscal Year 2025 Merit Medical Systems, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects Revenue of $1.470 billion to $1.490 billion, up 8% - 10% year-over-year. Buy Or Sell Opportunity • Jan 14
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 4.9% to US$99.89. The fair value is estimated to be US$82.42, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.7% over the last 3 years. Earnings per share has grown by 32%. For the next 3 years, revenue is forecast to grow by 6.8% per annum. Earnings are also forecast to grow by 13% per annum over the same time period. Ankündigung • Dec 20
Merit Medical Systems, Inc. Announces FDA Approval of the WRAPSody Cell-Impermeable Endoprosthesis Merit Medical Systems, Inc. announced that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025. WRAPSODY is designed to extend long-term vessel patency in dialysis patients. Many patients undergoing dialysis rely on a vascular access site created in the arm called an arteriovenous (AV) fistula (surgically joining an artery and vein) or an AV graft (a soft tube placed in the arm). The maintenance of adequate blood flow through these sites is crucial for patient survival. Over time, life-threatening access site complications can arise, including stenosis (narrowing of the vasculature) and thrombosis (blood clot formation). Each year in the United States, 687,000 procedures are performed to maintain dialysis access; nearly 100,000 of these procedures involve placement of a stent (a flexible woven metal tube, often with a covering) to preserve blood flow. While covered stents have improved long-term patency, stenosis is still common in patients receiving hemodialysis treatment. A key contributor to stenosis is the accumulation of tissue within the polytetrafluoroethylene (PTFE) layer of these devices. To address this challenge, in 2010, Merit engineers collaborated with Bart Dolmatch, MD, FSIR, Interventional Radiologist at Palo Alto Medical Foundation in Palo Alto, California, to develop the WRAPSODY Cell-Impermeable Endoprosthesis. The WRAPSODY Cell-Impermeable Endoprosthesis consists of a proprietary covering that features a nitinol stent frame enveloped by an expandable PTFE outer layer, an inner-luminal layer of novel “spun” PTFE designed to reduce platelet and fibrin formation,1 and a middle cell-impermeable layer designed to prevent transgraft tissue migration or accumulation.1 The nitinol frame provides enhanced radial force, compression resistance, and softened ends to help the device conform to vessels, withstand physiological compression, and reduce stress on vessel walls. Results from the WRAPSODY WAVE pivotal trial demonstrated that AV fistula and AV graft patients receiving treatment with the WRAPSODY device for dialysis outflow lesions achieved a target lesion primary patency of 89.8% and 82.0%, respectively, at six months. The primary patency of the entire access circuit at six months in patients with an AV fistula and AV graft were 72.6% and 68.8%, respectively. Ankündigung • Dec 17
Merit Medical Systems, Inc. Announces Resignation of Joseph C. Wright as President, Effective January 3, 2025 Merit Medical Systems, Inc. announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright’s resignation, Merit had received notice of allegations regarding his conduct, which Merit’s independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit’s operations or financial performance. Based upon Mr. Wright’s resignation, Merit’s Board of Directors has re-appointed Fred P. Lampropoulos as Merit’s President. 
